A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC
This clinical trial is studying an experimental medicine called TRI-611 for people with advanced non-small cell lung cancer. In some lung cancers, an altered gene produces a faulty protein called ALK, which signals cancer cells to grow and spread. TRI-611 is a tablet designed to destroy this harmful protein from within the cell. Because this is the first time TRI-611 is being given to humans, doctors first need to find out what dose is safest and how the body handles the medicine. They will also track how well the treatment shrinks tumours and prevents the cancer from growing. A key goal is checking whether TRI-611 can reach and treat tumours that have spread to the brain. Participants take tablets by mouth and attend regular hospital visits for blood tests, heart checks, and scans to ensure they stay safe.
At a glance
What is this study about?
Non-small cell lung cancer is the most common form of lung cancer. In some patients, the cancer is driven by a specific genetic change known as 'ALK-positive'. This change acts like a faulty switch, producing an abnormal ALK protein that tells cancer cells to multiply rapidly. While targeted medicines already exist to block this switch, cancers can develop resistance to them over time, making new treatment options essential.
TRI-611 is a new type of oral medicine known as a molecular glue degrader. Instead of just blocking the faulty ALK protein, it works by sticking to it and tagging it for disposal. The cancer cell's natural waste system then breaks down and destroys the protein entirely. Researchers hope this approach can overcome resistance and offer a more lasting way to stop tumour growth.
This trial combines Phase 1 and Phase 2, which means it is the first time the medicine is being tested in humans. In the first phase, doctors carefully test small, increasing doses to determine the safest and most effective dose. In the second phase, more patients will receive this chosen dose so researchers can measure how well it shrinks tumours, keeps cancer stable, and whether it can treat cancer that has spread to the brain.
By taking part, patients help scientists understand if TRI-611 could become a valuable future treatment for people living with ALK-positive lung cancer.
Key takeaways
- Tests a new oral tablet (TRI-611) for advanced ALK-positive non-small cell lung cancer.
- This is a first-in-human study to find a safe dose and look for side effects.
- Works by breaking down the faulty ALK protein driving cancer growth.
- Checks how well the drug shrinks tumours, including those in the brain.
- Open to adults aged 18 and over with confirmed ALK-positive cancer.
Who may be eligible?
This trial is open to adults aged 18 and over who have been diagnosed with advanced non-small cell lung cancer. 'Advanced' means the cancer has spread into surrounding tissues or to other parts of the body and cannot be completely removed by surgery alone.
To be considered, your tumour must test positive for the ALK gene change. People of all genders can join, provided they are well enough to attend regular clinic visits and take oral medication on their own.
Certain health conditions may prevent you from joining. For example, doctors will carefully check your liver, kidney, and heart function to make sure it is safe for you to take an experimental medicine. Pregnant or breastfeeding women will not be able to participate for safety reasons. Your cancer specialist can review your medical records to confirm if this trial matches your situation.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am at least 18 years old.
- I have been diagnosed with advanced non-small cell lung cancer.
- My cancer has been confirmed as ALK-positive through a lab test.
- I am able and willing to swallow tablets daily.
- I am able to attend frequent hospital appointments for tests and scans.
What does participation involve?
Taking part involves taking the study medicine, TRI-611, as a tablet by mouth at home. You will need to visit the hospital regularly for health checks, particularly during the first few weeks when doctors monitor how your body responds to the drug. These visits will include blood and urine tests, heart traces (ECGs), physical examinations, and regular imaging scans (such as CT or MRI scans) to track your tumours. The initial phase also requires extra blood samples to measure how the drug breaks down in your system. You can generally stay on the study treatment for as long as your cancer remains controlled and you do not experience unacceptable side effects. After finishing treatment, the medical team will continue to check in on your health.
Potential risks and benefits
Locations (4)
- —UnverifiedFrance
- —UnverifiedItaly
- —UnverifiedGermany
- —UnverifiedSpain
Common questions
What makes TRI-611 different from existing ALK treatments?
Most existing treatments simply block the ALK protein. TRI-611 is designed to completely break down and remove the protein, which scientists hope will work even if the cancer has become resistant to other drugs.
Do I have to stay overnight in the hospital?
No, you will take the tablets at home. However, you will need to attend regular day appointments at the clinic for tests, scans, and check-ups.
Can TRI-611 treat cancer that has spread to the brain?
Researchers are specifically testing how well TRI-611 works against tumours in the brain, as this is a common challenge in ALK-positive lung cancer.
What happens if I experience unpleasant side effects?
Your trial doctor will monitor you closely. If side effects occur, they may adjust your dose, pause the medication, give you medicines to treat the symptoms, or stop the study treatment if needed.
Will taking part cost me anything?
The study medicine and trial tests are provided free of charge. Many trials also offer support to cover reasonable travel expenses to and from hospital visits.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.